BCM
BHVN

Bluefin Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bluefin Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-58,900
Closed -$170K – 1088
2020
Q4 		$170K Buy
+58,900
New +$4.99M 0.01% 455

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Bluefin Capital Management's BHVN Position: Q4 2022 in Review

Bluefin Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 341,250 shares — an estimated $51.6M sold.

Bluefin Capital Management first reported a position in BHVN in Q1 2019 and held it in 6 quarters. The position peaked at $51.6M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Bluefin Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Bluefin Capital Management sold 341,250 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $51.6M.
  • Bluefin Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 6 quarters.
  • Bluefin Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $51.6M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Bluefin Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.